First quarter earnings for Allergan, maker of Botox, are way up. Second quarter forecasts, according to the Wall Street Journal, are way ahead of expectations.
Given the statistics just released by the ASPS, their success shouldn’t be all that surprising. According to the society, minimally invasive procedures have increased an incredible 99 percent since 2000. Topping the list are wrinkle fillers and botulinum toxin injections, two treatments in which plastic surgeons will likely reach for an Allergan product.
Image courtesy of the ASPS
For Allergan, being on the cutting-edge of aesthetic medicine also doesn’t hurt. New products like Juvederm Ultra XC and Latisse are getting plenty of attention right now, which should only increase consumer demand for these cosmetic procedures.
